Partner Content Partner Content Overwhelmed with KOL Data how to navigate through KOL insights & management
Partner Content Partner Content Summarising & Combining Insights Highlight, prioritize & combine your MSL insights
Views & Analysis Improving oncology KOL engagement Combining technology with human insights is a powerful tool in identifying and engaging effectively with oncology experts.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
